PharmAust is a unit of Epichem that contributed cash to the university to gain an additional 11% in the JV, proactiveinvestors.com.au reported.
It is believed that the treatment would be used as a front-line therapy to treat type 2 diabetics by delaying the onset of insulin-dependency.
The drug development project is still at the early discovery stage.